Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

Outcomes of Patients with Low Variant Allele Fraction JAK2V617F : A 5-Year Retrospective Analysis

Wasithep Limvorapitak, MD, Jeremy Parker, PhD, Lynda Foltz, MD FRCPC, Aly Karsan, MD

Blood (2018) 132 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2018-99-111592

Published: 2018

Journal Articles

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srdan Verstovsek, MD PhD, Robert P. Hasserjian, MD, Olga Pozdnyakova, MD PhD, Ivo Veletic, MD, Ruben A. Mesa, MD, Lynda Foltz, MD FRCPC, John Mascarenhas, MD, Ellen K. Ritchie, MD, Jeanne Palmer, MD, Richard T. Silver, MD, Marina Kremyanskaya, MD PhD, Bernt van den Blink, MD PhD, Renu Gupta, MD, Taghi Manshouri, PhD, C. Cameron Yin, MD PhD, Zeev E. Estrov, MD, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 686.

https://doi.org/10.1182/blood-2018-99-115362

Published: 2018

Journal Articles

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz, MD FRCPC, Gian-Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, MD, Sorin Visanica, MD, Enrique Báez de la Fuente, MD, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, MD, Mauricio Reyes Cartes, MD, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, PhD, Zhaoyu Yin, PhD, Juliane Morando, MD, Timothy Devos

Blood (2018) 132 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2018-99-111479

Published: 2018

NARROW

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Outcomes of Patients with Low Variant Allele Fraction JAK2V617F : A 5-Year Retrospective Analysis

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Email alerts

ASH Publications

American Society of Hematology

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Outcomes of Patients with Low Variant Allele Fraction JAK2V617F : A 5-Year Retrospective Analysis

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only